Navigation Links
AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SYMBICORT(R)

LONDON, Dec. 11 /PRNewswire-FirstCall/ -- On December 11, 2008, the Joint Advisory Committees of the U.S. Food and Drug Administration (FDA) - including the Drug Safety & Risk Management Advisory Committee, the Pediatric Advisory Committee, and the Pulmonary-Allergy Drugs Advisory Committee - completed a review of the benefits and risks of asthma medications containing long-acting beta-agonists (LABAs). The committees concluded that the benefits of AstraZeneca's SYMBICORT(R) (budesonide/formoterol fumarate dihydrate), a combination LABA/Inhaled Corticosteroid (ICS) medication, outweigh the risks in adult and adolescent asthma patients.

Howard Hutchinson, M.D., Chief Medical Officer of AstraZeneca, said, "The safety and efficacy of SYMBICORT have been demonstrated in numerous clinical trials and from extensive post-marketing use around the world. We are pleased that the joint advisory committees' recommendation confirms our view on the positive benefit-risk profile of SYMBICORT."

The FDA frequently convenes advisory committee meetings to obtain independent expert guidance and recommendations on clinical matters. While the FDA is not required to follow this guidance, the agency usually takes the advice into consideration when rendering its final decisions on pending applications and other public health matters.

About SYMBICORT in the U.S.

SYMBICORT(R) (budesonide/formoterol fumarate dihydrate) is approved in over 100 countries for the long-term maintenance treatment of asthma and is available in two different inhalers, SYMBICORT TURBUHALER and in the U.S. as SYMBICORT pMDI.

SYMBICORT is a combination therapy indicated in the U.S. for the long-term maintenance treatment of asthma in patients 12 years of age and older. SYMBICORT should not be used in patients whose asthma can be successfully managed by inhaled corticosteroids along with occasional use of inhaled short-acting beta2-agonists. Administered twice daily, SYMBICORT is a combination of two proven asthma medications-budesonide, an inhaled corticosteroid (ICS), and formoterol, a rapid and long-acting beta2-agonist (LABA). SYMBICORT does not replace fast-acting inhalers and should not be used to treat acute symptoms of asthma.

Important Safety Information

Long acting beta2-adrenergic agonists may increase the risk of asthma-related death. Therefore, when treating patients with asthma, SYMBICORT should only be used for patients not adequately controlled on other asthma-controller medications (e.g., low-to-medium dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with two maintenance therapies. Data from a large placebo-controlled U.S. study that compared the safety of another long-acting beta2-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol may apply to formoterol (a long-acting beta2-adrenergic agonist), one of the active ingredients in SYMBICORT.

SYMBICORT is not indicated for the relief of acute bronchospasm.

SYMBICORT should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of asthma.

Particular care is needed for patients who are transferred from systemically active corticosteroids. Deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids.

Patients who are receiving SYMBICORT twice daily should not use additional formoterol or other long-acting inhaled beta2-agonists for any reason.

Common adverse events reported in clinical trials, occurring in less than or equal to 5 percent of patients, regardless of relationship to treatment, included nasopharyngitis, headache, upper respiratory tract infection, pharyngolaryngeal pain, sinusitis, and stomach discomfort.

Please see full Prescribing Information and visit

Media Contacts US:

  • Michele Meeker 610-662-3589 (24 hours)

Media Contacts UK:

  • Neil McCrae +44 207 304 5045 (24 hours)
  • Chris Sampson +44 207 304 5130 (24 hours)

    Investor Enquiries UK:
    Jonathan Hunt      +44 207 304 5087        mob: +44 7775 704032
    Mina Blair         +44 207 304 5084        mob: +44 7718 581021
    Karl Hard          +44 207 304 5322        mob: +44 7789 654364

    Investor Enquiries US:
    Ed Seage                   +1 302 886 4065       mob: +1 302 373 1361
    Jorgen Winroth             +1 212 579 0506       mob: +1 917 612 4043
    Peter Vozzo (MedImmune)    +1 301 398 4358       mob: +1 301 252 7518

About AstraZeneca

AstraZeneca (NYSE: AZN) is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.35 billion dollar healthcare business with 12,200 employees committed to improving people's lives. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.

For more information visit

Broadcast quality footage is available to download from the Media section of our website at:

Journalists will be required to register to access this feature.

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
5. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
6. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
7. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
8. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
9. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
10. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
11. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
Post Your Comments:
(Date:10/12/2015)... October 12, 2015 --> ... "Spirometer Market by Product (Hand-held, Table-top, Desktop), Technology (Volume Measurement, ... & Geography - Global Forecast to 2020", published by MarketsandMarkets, ... by 2020, at a CAGR of 9.8% from 2015 to ... F igures spread th rough 187 P ...
(Date:10/12/2015)... DUBLIN , Oct. 12 2015 /PRNewswire/ ... announced the addition of the "Personalized ... to 2019 - Strategic Analysis of Industry ... to their offering. --> ... "Personalized Medicine, Targeted Therapeutics and Companion ...
(Date:10/12/2015)... , Oct. 12, 2015  To help address the ... Academy of Orthopaedic Surgeons (AAOS) Board of Directors ... physician, caregiver and patient education; the tracking of opioid ... support for more effective opioid abuse treatment programs. ... the AAOS Patient Safety Committee. "The new , AAOS ...
Breaking Medicine Technology:
(Date:10/12/2015)... ... October 12, 2015 , ... Amerec , a leader in the steam ... care equipment, will be displaying custom sauna and steam room solutions at the ISPA ... and spas as customers, SpaEquip is recognized for their ability to assist in the ...
(Date:10/12/2015)... CA (PRWEB) , ... October 12, 2015 , ... According ... Fire Chief for the city of San Antonio, Texas recommended that any high-rises in ... incorporate these important safety systems going forward. The article explains that it wasn’t until ...
(Date:10/12/2015)... , ... October 12, 2015 , ... At first glance, ... cocktail umbrella one would find atop a drink in a tiki bar. But the ... clinical trial at Allegheny General Hospital (AGH) could potentially signal a new way of ...
(Date:10/12/2015)... ... , ... Advera Health Analytics, Inc . is offering its exclusive ... in order to provide health plans, payers, systems, and hospitals with the ability to ... DSM is also being offered to healthcare media organizations to serve as an independent, ...
(Date:10/12/2015)... ... 2015 , ... To help raise awareness this October during ... National Breast Cancer Foundation. The National Breast Cancer Foundation is dedicated to providing ... education, and support services. , The annual campaign to increase breast cancer awareness ...
Breaking Medicine News(10 mins):